Russian government considering more public procurements of Rx drugs

5 November 2019
russia_roubles_rubles_money_big

The Russian government may consider the possibility of beginning public procurements of prescription drugs with their further provision to local population, according to recent statements, made by representatives of the Ministry of Health, reports The Pharma Letter’s local correspondent.

As Russian analysts said in the majority of developed countries, the provision of patients with prescription drugs is an integral part of their national health care systems, however, most of Russian citizens do not have an access to subsidized drugs, being forced to purchase them by themselves.

Last year, the Russian drug amounted to 1.5 trillion roubles ($45 billion). Of this total, 70% of drugs were purchased by local citizens themselves, another 20% by the state as part of public procurements, with the remaining 10% having the status of state-subsidized drugs. Of the drugs that are purchased by patients themselves, about half are prescription medicines.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical